Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide (Len) and pomalidomide trigger anti-tumor activities in multiple myeloma (MM) by targetting cereblon and thereby impacting IZF1/3, c-Myc and IRF4. Histone deacetylase inhibitors (HDACi) also downregulate c-Myc. We therefore determined whether...

Full description

Bibliographic Details
Main Authors: Hideshima, T, Cottini, F, Ohguchi, H, Jakubikova, J, Gorgun, G, Mimura, N, Tai, Y-T, Munshi, N C, Richardson, P G, Anderson, K C
Format: Online
Language:English
Published: Nature Publishing Group 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476017/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476017/

Similar Items